Boardroom Alpha
Start trial
Boardroom Alpha
RXST · Current Report (Form 8-K) · Filed June 16, 2026

Rxsight Inc — Current Report (Form 8-K)

Form
8-K
Filed
June 16, 2026
Period
Jun 16, 2026
Ticker
RXST
Accession
0001193125-26-272688
Rxsight Inc on Boardroom AlphaView on SEC EDGAR
Boardroom Alpha · Filing insights

Three Class II directors were reelected to terms through 2029. Stockholders approved the advisory vote on executive compensation and ratified Ernst & Young LLP as auditor.

About Rxsight Inc
Market cap
$248M
1Y TSR
−28.8%
3Y TSR
−38.8%
Board grade
C+
Sector
Healthcare
CEO
Aziz Mottiwala
Last annual meeting: Jun 16, 2026 · View full Rxsight Inc profile →
8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2026

 

 

RxSight, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40690

94-3268801

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

100 Columbia

 

Aliso Viejo, California

 

92656

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (949) 521-7830

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

RXST

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

We held our 2026 Annual Meeting of Stockholders (“Annual Meeting”) on June 16, 2026. Of the 41,396,609 shares of our common stock outstanding as of April 21, 2026, 33,299,192 shares of common stock were represented, either by attending the virtual annual meeting or by proxy, constituting, of the shares entitled to vote, approximately 80.4% of the outstanding shares of common stock. The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below.

 

1.
Election of Three Class II Directors. The following nominees were re-elected by the holders of our common stock to serve as our Class II directors to hold office until our 2029 annual meeting of stockholders and until their successors have been duly elected and qualified:

Nominee

 

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

William J. Link

 

 

21,086,793

 

 

 

—

 

 

 

2,935,396

 

 

 

9,277,003

 

Robert Warner

 

 

15,667,180

 

 

 

—

 

 

 

8,355,009

 

 

 

9,277,003

 

Shweta Singh Maniar

 

 

13,850,389

 

 

 

—

 

 

 

10,171,800

 

 

 

9,277,003

 
2.
Advisory Vote on Executive Compensation. The stockholders approved, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement based on the following results of voting:

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

 

21,236,615

 

 

 

2,742,189

 

 

 

43,385

 

 

 

9,277,003

 
3.
Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting:

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

 

33,062,585

 

 

 

92,653

 

 

 

143,954

 

 

 

—

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

RxSight, Inc.

 

 

 

 

Date:

June 16, 2026

By:

/s/ Mark Wilterding

 

 

 

Name: Mark Wilterding
Title: Chief Financial Officer

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

See Filings IntelligenceSchedule a Demo

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Rxsight Inc (RXST)

Continue researching
Reference

Frequently asked questions

When did Rxsight Inc file this 8-K?
Rxsight Inc (RXST) filed this Current Report (Form 8-K) with the SEC on June 16, 2026. The accession number assigned by EDGAR is 0001193125-26-272688.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Three Class II directors were reelected to terms through 2029. Stockholders approved the advisory vote on executive compensation and ratified Ernst & Young LLP as auditor. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Rxsight Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Rxsight Inc has filed under CIK 1111485, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer